Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of **placebo + acetylcysteine** refers to a specific experimental arm in a pilot clinical trial (NCT01384591) sponsored by the University of Texas Medical Branch, Galveston. In this study, healthy elderly subjects (ages 60–85) received active N-acetylcysteine (NAC) at a dose of 50 mg/kg alongside a placebo for losartan. N-acetylcysteine is a small molecule antioxidant and a precursor to glutathione, a critical endogenous antioxidant. The research investigated whether NAC could improve skeletal muscle blood flow and reduce fatigue, addressing age-related declines in nutritive muscle perfusion and muscle-building capacity (sarcopenia risk). By replenishing glutathione levels, NAC aims to mitigate oxidative stress pathways that contribute to muscle dysfunction in aging populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + acetylcysteine.